A5053952702- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- vaccines and immunoinformatics approaches
- Cervical Cancer and HPV Research
- Psychoanalysis and Psychopathology Research
- Ocular Oncology and Treatments
- T-cell and B-cell Immunology
- Cancer Genomics and Diagnostics
Immunité et Cancer
2024
Inserm
2024
Institut Curie
2022-2024
Etablissements de Santé Mentale
2022
Uveal melanoma (UM) is the most common cancer of eye. The loss chromosome 3 (M3) associated with a high risk metastases. M3 tumors are more infiltrated by T-lymphocytes than low-risk disomic-3 (D3) tumors, contrasting other tumor types in which T cell infiltration correlates better prognosis. Whether these cells represent an antitumor response and how would be primed eye both unknown. Herein, we characterized infiltrating primary UMs. CD8+ Treg were abundant D3 tumors. CD39+PD-1+CD8+...
6082 Background: Despite adjuvant therapy, over 50% of surgically treated head and neck squamous cell carcinoma (HNSCC) patients (pts) experience a recurrence disease. Systemic stimulation cellular immunity against tumor mutations using viral vaccine may be an ideal modality to clear residual cancer cells. For this purpose, we developed pipeline for the design TG4050, personalized (PCV) Modified Vaccinia Ankara (MVA) vector. We report here preliminary safety immunogenicity data from phase I...
2637 Background: Mutation-associated neoantigens (MANAs) constitute attractive antigens for the design of cancer vaccines. However, clinical implementation remains challenging because patient specific nature MANAs, hereby requiring that a bespoke vaccine is designed each subject. We developed pipeline genomic characterization and tailored using modified vaccinia Ankara viral vector. Methods: Immunogenicity, safety early activity personalized vaccines are being assessed in two phase I trials,...
<h3>Background</h3> T cells targeting tumor specific mutations drive anti-tumor immune responses. TG4050 is a novel viral-based personalized cancer vaccine, encoding up to 30 patient- and tumor-specific sequences bearing in-silico predicted class I II epitopes. may prime an adaptive response against antigens prevent relapse in patients with locally advanced resected HNSCC. (NCT04183166) <h3>Methods</h3> Eligible stage III or IV HPV-negative HNSCC were randomized after completion of standard...
Abstract Background: Head and Neck (HNSCC) Ovarian cancer (OC) are two indications for which immunotherapy had limited impact so far. Current treatments achieve high rates of initial success through surgery adjuvant chemo/radiotherapy, but patients (pts) remain at risk relapse in both indications. Immune stimulation using a vaccine is promising strategy to clinically meaningful improvement. Herein we report phase I data TG4050, engineered carry pt tailored antigen payload, pts with HNSCC...
2630 Background: Human papillomavirus 16 (HPV-16) infection is associated with several cancer types limited treatment options in the locally R/M settings. Furthermore, immune checkpoint inhibitors have activity against advanced HPV-cancers. TG4001 a viral vector vaccine targeting HPV E6 and E7 antigens. We previously shown single-arm, dose finding phase 1 study that combined PD-L1 blockade using avelumab was safe response rate of 22%. Herein we report preliminary data on immunogenicity...
Souffrances donc soins, discrétion voire diversion, humilité et minutie, décentration puis narration, appréhension mais transformation, réparation pour sublimation… autant de semences d’allégories, où les plantes se révèlent être d’élégantes alliées au sein des psychothérapies.